OKYO Pharma (OKYO) CMO adds 20,000 shares in open-market buy
Rhea-AI Filing Summary
OKYO Pharma Ltd disclosed that Chief Medical Officer Flavio Mantelli purchased 20,000 shares of common stock in an open-market transaction on July 21, 2026 at $1.40 per share, resulting in direct holdings of 20,000 shares. This Form 4/A filing solely corrects the transaction code on the earlier report; no other transactions are changed.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 20,000 shares
Net Buy
1 txn
Insider
Mantelli Flavio
Role
CHIEF MEDICAL OFFICER
Bought
20,000 shs ($28K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | COMMON STOCK | 20,000 | $1.40 | $28K |
Holdings After Transaction:
COMMON STOCK — 20,000 shares (Direct)
Key Figures
Shares purchased: 20,000 shares
Purchase price per share: $1.40 per share
Shares owned after transaction: 20,000 shares
+1 more
4 metrics
Shares purchased
20,000 shares
Open-market purchase of common stock on July 21, 2026
Purchase price per share
$1.40 per share
Price paid in the July 21, 2026 open-market transaction
Shares owned after transaction
20,000 shares
Directly held OKYO Pharma common stock following the purchase
Buy transactions in filing
1 transaction
Single reported open-market purchase in this Form 4/A
Key Terms
Form 4/A, transaction code, open market purchase
3 terms
Form 4/A regulatory
"This Form 4/A amends the Form 4 filed on July 22, 2026 solely"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
transaction code regulatory
"solely to correct the transaction code associated with this open market purchase"
open market purchase financial
"transaction code associated with this open market purchase"
An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did OKYO (OKYO) report for Flavio Mantelli?
Flavio Mantelli, Chief Medical Officer of OKYO Pharma, purchased 20,000 shares of common stock in an open-market transaction on July 21, 2026 at a price of $1.40 per share, according to the filing.
What does this Form 4/A amendment change for OKYO (OKYO)?
The amendment states it only corrects the transaction code associated with the July 21, 2026 open-market purchase. It specifies that no other reported transactions in the original filing are affected or changed by this correction.
Does this OKYO (OKYO) Form 4/A report any new insider trades?
The amendment explains it was filed solely to correct the transaction code for the previously reported July 21, 2026 purchase and confirms that no other reported transactions are affected, indicating no new trades are introduced.